Colitis is considered a significant risk factor for the development and progression of colorectal cancer due to excessive inflammation formed as a result of inflammatory bowel disease (IBD), which is linked to colorectal cancer development. Colorectal cancer often lacks overt symptoms in its early stages, leading to late-stage diagnosis in most patients. Therefore, timely diagnosis and differentiation of colitis and colorectal cancer are crucial. This study introduces a novel activatable carboxylesterase 2 (CES2) fluorescent probe, DBF-CES2, consisting of a cationic indolium fluorophore and a CES2-specific benzyl ester recognition group. The probe operates via the intramolecular charge transfer (ICT) mechanism. Upon binding and hydrolysis by CES2, a potent electron-donating hydroxyl group is released, enhancing the ICT effect and increasing fluorescence intensity, emitting red fluorescence light (λem = 680nm). The probe had a large Stokes shift of 167nm and a detection limit as low as 0.70ng/mL. It also had high selectivity, sensitivity, and biocompatibility. Cellular imaging experiments demonstrated that CES2 expression levels in colorectal cancer cells were higher than those in normal cells. The DBF-CES2 probe specifically recognized endogenous CES2 in colorectal cancer cells, promptly distinguishing them from normal cells. In vivo imaging in mice confirmed that the probe could differentiate between colitis and colorectal cancer, allowing for the assessment of the therapeutic effects of two drugs. The synthesized CES2-targeting organic small molecule fluorescent probe DBF-CES2 is a new molecular tool for the early diagnosis of colitis and colorectal cancer-related diseases, holding significant potential in clinical diagnostics.
Read full abstract